June 2026
Core topics in this month’s edition include:
- Tregzi™ (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) – New drug approval
- Ibrance® (palbociclib) – New indication
- Bosulif® (bosutinib) – First-time generic
- Pfizer – Discontinuation of Vizimpro® (dacomitinib) tablets